Home Magazines Editors-in-Chief FAQs Contact Us

Dabigatran as alternative therapy in prothrombotic immune thrombocytopenia induced by the AstraZeneca SARS-Cov-2 vaccine  


Journal of Cardiology & Current Research
Juan José Cerezo Manchado, Teodoro Iturbe Hernández

PDF Full Text

Abstract

Reviewing the treatment alternatives for thormbotic thrombocytopenia induced by vaccine (TTIV) after receiving a dose of ChAdOx1 nCov-19 vaccine (AstraZeneca) we observe that dabigatran should be an alternative to be considered since it has several strength points that may be useful in this pathology: Specific antidote, low level of interactions with others drugs and effectiveness in thrombotic events.

Keywords

TTIV, thrombotic thrombocytopenia induced by vaccine, HIT, heparin-induced thrombocytopenia, DOAC, direct-acting oral anticoagulants, CVT, cerebral venous thrombosis, SVT, splanchnic venous thrombosis, ISTH, international society on thrombosis and haemostasis, EHRA, european heart rhythm association

Testimonials